Across TCGA pan-cancer cohorts, CDCA2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CDCA2 data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CDCA2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CDCA2 expression acts as an unfavorable survival marker.

UCEC, LSCC, and PDAC are the cancer types where CDCA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Quartile	All	0.864	1.000	.011	10	view →
LSCC	DFS	Median	III,IV	0.810	1.000	.012	8	view →
PDAC	DFS	Tertile	All	0.743	0.900	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CDCA2 tumor-vs-normal RNA expression · all CDCA2 data types